Cancer treatment could become more affordable for patients in India following a government move to strengthen price controls on non-scheduled cancer medicines. Under the proposed measures, profit margins on the distribution and sale of these medicines would be capped at 30% of the maximum retail price (MRP). The initiative is expected to reduce the prices of certain medicines by as much as 70% and potentially save patients around Rs 2,500 crore annually.
The move aims to address the high cost of cancer medicines and reduce the financial pressure on patients and their families.
NPPA Identifies High Markups on Cancer Medicines
The Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilizers, stated that the National Pharmaceutical Pricing Authority (NPPA) found an average markup of approximately 170% on non-scheduled cancer medicines. In some cases, the markup reportedly reached 700% or more, creating a substantial difference between supply-chain costs and the prices paid by patients.
Price variations have also been observed among medicines sold through retail pharmacies, hospital pharmacies and online platforms. The proposed restrictions seek to address excessive markups and improve affordability for people undergoing cancer treatment.
Which Cancer Medicines Will Be Covered?
The proposed price-control measures target non-scheduled cancer medicines that are not included in the government’s existing price-controlled list. The coverage includes branded and generic products, as well as medicines manufactured in India or imported from other countries, whether patented or non-patented.
An expert committee established under the Directorate General of Health Services (DGHS) will identify the medicines covered by the measures. The NPPA will issue the relevant guidelines through official notifications.
The initiative is intended to extend price regulation beyond the medicines already covered by existing controls and address significant price differences in the wider cancer-drug market.
Previous Price Controls Reduced Medicine Costs
In February 2019, the government introduced restrictions on profit margins for 42 non-scheduled cancer medicines. That measure led to a reduction of up to 91% in the maximum retail prices of 526 drug brands, generating estimated annual savings of around Rs 984 crore.
The latest initiative seeks to build on that earlier measure and extend the benefits of price regulation to a broader range of cancer medicines.
Manufacturers will also be required to maintain their existing production levels to help ensure that patients continue to have access to the medicines they need.
What the Move Could Mean for Cancer Patients
Cancer treatment can place a significant financial burden on patients and their families, particularly when expensive medicines are required over an extended period. Limiting distribution and retail profit margins could help reduce out-of-pocket expenses for eligible medicines.
However, the actual price reduction will depend on the medicines covered, the implementation of the proposed measures and the applicable official notifications. Patients should check the latest information before assuming that a particular medicine’s price has been reduced.
Disclaimer
This article is intended for general informational purposes only and should not be considered medical, financial or legal advice. The expected price reductions and estimated savings are based on the information provided and should not be interpreted as guaranteed outcomes. The scope and implementation of the price-control measures will depend on official government notifications and applicable regulations. Patients should consult healthcare professionals regarding treatment decisions and verify medicine prices through authorised pharmacies or official sources.